Related Experiment Video

Updated: Dec 26, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

889

A potential new target for autoinflammatory bone disease

Elizabeth L Hartland1

  • 1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research and Department of Molecular and Translational Science, Monash University, Clayton, Victoria 3168, Australia.

The Journal of Biological Chemistry
|March 15, 2020
PubMed

Insights

Spleen tyrosine kinase (SYK) plays a key role in chronic recurrent multifocal osteomyelitis (CRMO) by up-regulating the inflammatory cytokine IL-1β. Targeting SYK may offer a new therapeutic strategy for this autoinflammatory bone disease.

Area of Science:

  • Immunology
  • Bone Biology
  • Inflammation Research

Background:

  • Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease characterized by bone lesions.
  • Interleukin-1 beta (IL-1β) is a key inflammatory cytokine driving CRMO pathogenesis.
  • The precise signaling pathways leading to elevated IL-1β in CRMO remain incompletely understood.

Purpose of the Study:

  • To investigate the upstream signaling mechanisms regulating IL-1β production in CRMO.
  • To identify potential novel therapeutic targets for CRMO.

Main Methods:

  • Utilized a genetic mouse model that recapitulates key features of CRMO.
  • Analyzed the role of spleen tyrosine kinase (SYK) in the inflammatory signaling cascade.

Main Results:

  • Identified a critical role for the nonreceptor tyrosine kinase, SYK, in the signaling pathway.
  • Demonstrated that SYK activity is essential for the up-regulation of IL-1β in the CRMO mouse model.
  • SYK acts upstream in the signaling cascade leading to pathogenic IL-1β levels.

Conclusions:

  • Spleen tyrosine kinase (SYK) is implicated in the pathogenesis of CRMO.
  • SYK represents a potential novel therapeutic target for managing CRMO.
  • Further research into SYK inhibition could lead to new treatment strategies for CRMO.

More Related Videos

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes11:52

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

4.2K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.0K

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K